Ftse Mib
35.090,23
-0,64%
DAX
20.214,79
-0,51%
S&P 500
5.827,04
-1,54%
NASDAQ
19.161,63
-1,63%
Bitcoin
93.827,16
-0,79%
Pepperstone
Advertisement
Registration Strip Icon for monitor Monitora più quotazioni in tempo reale dalle principali borse, come Borsa Italiana, NASDAQ, NYSE, AMEX, Bovespa e altro ancora.
Registrati

Quotazioni in diretta

Non abbiamo trovato risultati per:
Assicurati di aver scritto correttamente o prova ad allargare la ricerca.

Più Attivi

Toplist

Sembra che tu non sia connesso.
Clicca il pulsante qui sotto per accedere e visualizzare la tua cronologia recente.

Registrati

Sei già registrato? Accedi

Pepperstone

Inizia Ora

Pepperstone
Home Investire Azioni U.S.A. NASDAQ Neurocrine Biosciences Inc (NBIX) Neurocrine Biosciences Inc (NBIX) Notizie

NBIX

Neurocrine Biosciences (NBIX)

HOME News News di Agenzia

News di Agenzia

Da:
 Ti mostriamo gli articoli più rilevanti per la tua ricerca:NASDAQ:NBIX
DataOraFonteTitoloSimboloCompagnia
08/01/202514:30PR Newswire (US)Neurocrine Biosciences Announces Publication on Traditional Glucocorticoid Treatment in Classic Congenital Adrenal Hyperplasia in Expert Review of Endocrinology & MetabolismNASDAQ:NBIXNeurocrine Biosciences Inc
06/01/202522:01PR Newswire (US)Neurocrine Biosciences to Present at the 43rd Annual J.P. Morgan Healthcare ConferenceNASDAQ:NBIXNeurocrine Biosciences Inc
03/01/202522:23Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:NBIXNeurocrine Biosciences Inc
31/12/202422:17Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:NBIXNeurocrine Biosciences Inc
20/12/202414:06Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:NBIXNeurocrine Biosciences Inc
20/12/202414:00PR Newswire (US)Neurocrine Biosciences Announces Commercial Availability of CRENESSITY™ (crinecerfont) for Children and Adults With Classic Congenital Adrenal HyperplasiaNASDAQ:NBIXNeurocrine Biosciences Inc
14/12/202400:55PR Newswire (US)Neurocrine Biosciences Announces FDA Approval of CRENESSITY™ (crinecerfont), a First-in-Class Treatment for Children and Adults With Classic Congenital Adrenal HyperplasiaNASDAQ:NBIXNeurocrine Biosciences Inc
26/11/202422:01PR Newswire (US)Neurocrine Biosciences to Participate at Investor Conferences in DecemberNASDAQ:NBIXNeurocrine Biosciences Inc
07/11/202414:30PR Newswire (US)Neurocrine Biosciences Presents New KINECT®-HD Data Showing Consistent Efficacy Across 19 Subgroups and Improvements in Aspects of Emotional Health With INGREZZA® (valbenazine) CapsulesNASDAQ:NBIXNeurocrine Biosciences Inc
05/11/202422:01PR Newswire (US)Neurocrine Biosciences to Participate at Investor Conferences in NovemberNASDAQ:NBIXNeurocrine Biosciences Inc
04/11/202414:30PR Newswire (US)Neurocrine Biosciences Presents Breadth of Data Demonstrating Holistic Improvements Over Time in Patients With Tardive Dyskinesia Following Treatment With INGREZZA® (valbenazine) CapsulesNASDAQ:NBIXNeurocrine Biosciences Inc
04/11/202414:25PR Newswire (US)Neurocrine Biosciences Presents New Data on INGREZZA® (valbenazine) Capsules at Psych Congress 2024: Majority of Long-Term Study Participants Achieved Remission of Tardive DyskinesiaNASDAQ:NBIXNeurocrine Biosciences Inc
30/10/202412:04Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:NBIXNeurocrine Biosciences Inc
30/10/202412:00PR Newswire (US)Neurocrine Biosciences Reports Third Quarter 2024 Financial Results and Raises 2024 INGREZZA Sales GuidanceNASDAQ:NBIXNeurocrine Biosciences Inc
09/10/202422:01PR Newswire (US)Neurocrine Biosciences Announces Conference Call and Webcast of Third Quarter 2024 Financial ResultsNASDAQ:NBIXNeurocrine Biosciences Inc
30/09/202414:30PR Newswire (US)Neurocrine Biosciences Presents Interim Data Demonstrating Robust and Sustained Improvements in Chorea Associated With Huntington's Disease Through Week 104 Irrespective of Antipsychotic UseNASDAQ:NBIXNeurocrine Biosciences Inc
19/09/202422:01PR Newswire (US)Neurocrine Biosciences to Participate at the TD Cowen 4th Annual Novel Mechanisms in Neuropsychiatry Virtual SummitNASDAQ:NBIXNeurocrine Biosciences Inc
12/09/202422:05PR Newswire (US)Neurocrine Biosciences Provides Update on ERUDITE™ Phase 2 Data for Luvadaxistat in Adults with Cognitive Impairment Associated with SchizophreniaNASDAQ:NBIXNeurocrine Biosciences Inc
10/09/202422:01PR Newswire (US)Neurocrine Biosciences to Participate at the 2024 Cantor Global Healthcare ConferenceNASDAQ:NBIXNeurocrine Biosciences Inc
28/08/202422:05PR Newswire (US)Neurocrine Biosciences to Participate at Investor Conferences in SeptemberNASDAQ:NBIXNeurocrine Biosciences Inc
28/08/202413:00PR Newswire (US)Neurocrine Biosciences Reports Positive Phase 2 Data for NBI-1117568 in Adults with SchizophreniaNASDAQ:NBIXNeurocrine Biosciences Inc
07/08/202422:01PR Newswire (US)Neurocrine Biosciences to Present at the Canaccord Genuity 44th Annual Growth ConferenceNASDAQ:NBIXNeurocrine Biosciences Inc
01/08/202416:51Edgar (US Regulatory)Form S-8 - Securities to be offered to employees in employee benefit plansNASDAQ:NBIXNeurocrine Biosciences Inc
01/08/202413:00PR Newswire (US)Neurocrine Biosciences Reports Second Quarter 2024 Financial Results and Raises 2024 INGREZZA Sales GuidanceNASDAQ:NBIXNeurocrine Biosciences Inc
18/07/202414:30PR Newswire (US)Neurocrine Biosciences Launches INGREZZA® SPRINKLE (valbenazine) Capsules to Ease Administration for Patients Experiencing Dysphagia or Difficulty SwallowingNASDAQ:NBIXNeurocrine Biosciences Inc
11/07/202422:01PR Newswire (US)Neurocrine Biosciences Announces Conference Call and Webcast of Second Quarter 2024 Financial ResultsNASDAQ:NBIXNeurocrine Biosciences Inc
01/07/202413:30PR Newswire (US)Neurocrine Biosciences Announces U.S. FDA Accepts New Drug Applications and Grants Priority Review for Crinecerfont for Pediatric and Adult Patients with CAHNASDAQ:NBIXNeurocrine Biosciences Inc
03/06/202414:01PR Newswire (US)Neurocrine Biosciences Presented CAHtalyst™ Phase 3 Pediatric and Adult Studies, CAHtalog™ Registry and Disease- and Glucocorticoid-Related Comorbidities Data in CAH at ENDO 2024NASDAQ:NBIXNeurocrine Biosciences Inc
03/06/202413:35PR Newswire (US)Neurocrine Biosciences Announces Publication of Primary CAHtalyst™ Pediatric Phase 3 Study Results of Crinecerfont for the Treatment of CAH in The New England Journal of MedicineNASDAQ:NBIXNeurocrine Biosciences Inc
03/06/202413:30PR Newswire (US)Neurocrine Biosciences Announces Publication of Primary CAHtalyst™ Adult Phase 3 Study Results of Crinecerfont for the Treatment of CAH in The New England Journal of MedicineNASDAQ:NBIXNeurocrine Biosciences Inc
 Ti mostriamo gli articoli più rilevanti per la tua ricerca:NASDAQ:NBIX

La tua Cronologia

BIT
P1L7Z0
BNP Paribas Issuance
LSE
SOHO
Social Housing Reit
Delayed Upgrade Clock
Per accedere al tempo reale push di Borsa è necessario registrarsi.

Il sito ADVFN Italia è stato realizzato ed è gestito da PRODESFIN su licenza di ADVFN PLC.

PER CONTATTI E PUBBLICITA' SUL SITO CLICCARE QUI

Accedendo ai servizi offerti da ADVFN, ne si accettano le condizioni generali Termini & Condizioni

ADVFN Network